Share
USER HOTLINE: call us at +49 30 65499 145 | Not all products are available in the USA.
Studies and Registries

Access the latest studies, insights, and literature to improve care.

Expertise and clinical evidence

The introduction of new extracorporeal therapies for critically ill patients requires rigorous medical and scientific effort to demonstrate safety, efficacy, and clinical outcome benefits. This foundation is essential for the proper application, acceptance, and recommendation of the therapy as a standard adjunctive treatment, and for securing reimbursement within healthcare systems.

Because of this, we are continually expanding and enhancing the knowledge and clinical evidence supporting our therapies, making this information widely available to our clinical application partners.

  • Multicentric Studies

    CytoSorbents has initiated numerous multicentric trials in cardiac surgery, septic shock, and critical care. Published studies validate CytoSorb’s safety and efficacy. Ongoing investigator-initiated trials, some actively recruiting and others completed, continue to confirm its effectiveness. Among others, projects in shock reversal in vasoplegic septic shock (PROCYSS study) and left-ventricular assist device implantation are underway. The STAR-T trial in the USA has now completed. An increase in published clinical data is expected, as several projects are nearing completion or already completed.

    CytoSorbents study ID
    Category
    Country
    Site
    Patient No.
    Status
    Registration
    S18 PROCYSS study Germany 20 260 Recruiting Resource
    O06 COSMOS Registry International Multiple 3000 Recruiting Resource
    P01 Pancreatitis Germany Technical University Munich, Hospital Weiden 30 Published Resource
    CSI01 Cardiopulmonary bypass intraoperative (infective endocarditis / REMOVE) Germany 14 sites 250 Published Resource
    CT Reg COVID-19 CTC Registry USA Multiple 100 Published Resource
    S14 Septic Shock (MiHaS) Germany 3 sites 40 Data analysis Resource
    CSI08 Cardiopulmonary bypass intraoperative UK, Netherlands 2 sites 60 Recruiting Resource
    STAR Antithrombotic removal registry International Multiple 500 Recruiting Resource
    STAR-T Cardiopulmonary bypass intraoperative USA Multiple 120 Data analysis Resource
  • Monocenter Studies

    Renowned clinics all over the globe are studying the effectiveness of CytoSorbents’ solutions in various hyperinflammatory conditions. Research spans high-risk cardiac surgery on bypass, refractory septic shock, burns, and liver failure. Numerous investigator-initiated trials are in progress, with some recruiting or completed. Ongoing and upcoming projects indicate a continued surge in published evidence on the effectiveness and clinical outcomes of CytoSorb Therapy.

    CytoSorbents study ID
    Category
    Country
    Site
    Patient No.
    Status
    Registration
    Tx04 Orthotopic Heart Transplantation Hungary Semmelweis University, Budapest 60 Published Resource
    SepsAR3 Septic Shock Netherlands University Medical Centre, Mainz 150 Recruiting Resource
    S21 Septic Shock Netherlands Nijmegen Radboud UMC 24 Published Resource
    S19 Septic Shock Germany Hamburg University Hospital Hamburg-Eppendorf, Hamburg 32 Recruiting Resource
    O930 VA ECMO (cardiogenic shock) Germany Jena University Hospital 54 Recruiting Resource
    O921 COVID-19 Belgium CHU Brugmann, Brussels 24 Data analysis Resource
    O03 Cytokine Release Syndrome Germany Hannover Medical School 34 Recruiting Resource
    EC05 Post arrest requiring eCPR Germany Freiburg University Hospital, Freiburg 20 Published Resource
    CYTOCOV-19 COVID-19 patients Germany Hamburg University Hospital Hamburg – Eppendorf, Hamburg 24 Published Resource
    Cyto-HOPE Liver Transplant Italy Papa Giovanni XXIII Hospital, Bergamo 20 Recruiting Resource
    CSI26 Cardiac Surgery Netherlands LUMC Leiden 36 Recruiting Resource
    CSI22 Cardiac Surgery Sweden Sahlgrenska University Hospital Gothenburg 20 Published Resource
    CSI16 Cardiac Surgery Switzerland Dept of Intensive Care Medicine, Bern 54 Recruiting Resource
    CSI06 Cardiopulmonary bypass intraoperative Germany Nuremberg hospital 40 Publication phase Resource
    CGS01 Post cardiac arrest Switzerland Centre Hospitalier Universitaire, Vaudois, Lausanne 40 Published Resource
  • The CytoSorb Registries

     


    The COSMOS
    (CytoSorb TreatMent OF Critically Ill PatientS) registry was opened in mid-2022 and is a company-sponsored international registry designed to provide an infrastructure for the ongoing surveillance of CytoSorb use in real-world critical-care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient selection for CytoSorb and related treatment modalities. Recruitment is ongoing.

     


    The STAR
    (Safe and Timely Antithrombotic Removal) registry was first registered with ClinicalTrials.gov in Sept 2021 and is a company sponsored multicentric European Registry designed to capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents. Recruitment is ongoing.

CytoSorbents

Voices around the world

world map
Critical Care
Dr. Gabriella Bottari
Italy, Rome

We have applied CytoSorb in critical ill children with septic shock, with very good results.

Critical Care
Dr. Willem Pieter Brouwer
The Netherlands, Rotterdam

Intervention with CytoSorb may be associated with decreased all-cause mortality at 28 days compared to continuous renal replacement therapy alone.

Critical Care
Prof. Pedja Kovacevic
Bosnia and Herzegovina, Banja Luka

This case series describes potential positive effects of hemoadsorption in preventing the development of systemic hyperinflammation after vvECMO in ARDS.